Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 22, No 10 (May 15), 2004: pp. 2035-a
© 2004 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2004.99.052

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Small, E. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Small, E. J.
Related Articles
Right arrowRelated Article

CORRESPONDENCE

In Reply:

Eric J. Small

University of California San Francisco, San Francisco, CA.

In response to the points raised, there was no provision for patients to receive calcium and vitamin D during this trial.1 Although serum calcium was not measured at 3 to 7 days after the administration of pamidronate, it was measured at week 3 and every 3 weeks thereafter. There were no clinical manifestations of hypocalcemia, and in fact, no differences in the frequency of hypocalcemia between the pamidronate and placebo cohorts (< 1%) were observed. Undoubtedly more episodes of asymptomatic hypocalcemia would have been observed had laboratory measurements been obtained more frequently.

Although the frequency of hypocalcemia is low, the frequency of subclinical vitamin D deficiency2 and the potential for severe hypocalcemia in patients with occult vitamin D deficiency3 warrant supplementation with both vitamin D and calcium for men receiving bisphosphonates for metastatic prostate cancer.

Author's Disclosures of Potential Conflicts of Interest

The author indicated no potential conflicts of interest.

REFERENCES

1. Small EJ, Smith MR, Seaman JJ, et al: Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 21:4270-4276, 2003[Abstract/Free Full Text]

2. Smith MR, McGovern FJ, Zietman AL, et al: Pamidronate to prevent bone loss during androgen deprivation therapy for prostate cancer. N Engl J Med 345:948-955, 2001[Abstract/Free Full Text]

3. Rosen CJ, Brown S: Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med 348:1503-1504, 2003[Free Full Text]


Related Article

  • Pamidronate, Hypocalcemia, and Calcium and Vitamin D Supplementation
    Ozden Altundag and Kadri Altundag
    JCO 2004 22: 2035 [Full Text]



This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Small, E. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Small, E. J.
Related Articles
Right arrowRelated Article

About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2004 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online